|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
MATERNAL SERUM AFP
Test CodeLAB3761
Quest Code
5059X
CPT Codes
82105
Includes
AFP, Maternal Risk Interpretation
Preferred Specimen
1 mL (0.5 mL minimum) serum
Transport temperature: Room temperature
Prenatal risk assessment for open neural tube defects
(NTDs).
For manual orders use 'Maternal Serum Screen Req.'
The Maternal Serum Alpha Feto-Protein (MSAFP) test in
pregnant women should be performed between 15.0 and
22.9 weeks gestational age, although the optimal period
is 15.0-16.9 weeks. This time frame allows sufficient
opportunity for further diagnostic studies if the
initial MSAFP results are abnormal. Specimens submitted
before 15.0 weeks or after 22.9 weeks gestation cannot
be properly evaluated. Because MSAFP test results are
influenced by certain patient characteristics, the
following data must be provided with the specimen in
order to permit accurate interpretation of results: date
of collection, patient's (maternal) date of birth,
patient's estimated date of delivery (EDD), patient's
weight (in lbs.), patient's race, patient diabetic
status (is patient insulin-dependent prior to pregnancy)
number of fetuses, and whether this is a repeat sample.
Transport temperature: Room temperature
Prenatal risk assessment for open neural tube defects
(NTDs).
For manual orders use 'Maternal Serum Screen Req.'
The Maternal Serum Alpha Feto-Protein (MSAFP) test in
pregnant women should be performed between 15.0 and
22.9 weeks gestational age, although the optimal period
is 15.0-16.9 weeks. This time frame allows sufficient
opportunity for further diagnostic studies if the
initial MSAFP results are abnormal. Specimens submitted
before 15.0 weeks or after 22.9 weeks gestation cannot
be properly evaluated. Because MSAFP test results are
influenced by certain patient characteristics, the
following data must be provided with the specimen in
order to permit accurate interpretation of results: date
of collection, patient's (maternal) date of birth,
patient's estimated date of delivery (EDD), patient's
weight (in lbs.), patient's race, patient diabetic
status (is patient insulin-dependent prior to pregnancy)
number of fetuses, and whether this is a repeat sample.
Minimum Volume
0.5 mL
Specimen Stability
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 45 days
Refrigerated: 14 days
Frozen: 45 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Grossly lipemic, grossly icteric, EDTA or heparinized
plasma.
plasma.
Methodology
Immunoassay (IA)
Setup Schedule
Set up: Mon-Fri; Report available; 3-5 days from set up
Report Available
3-5 Days from set up
Limitations
MSAFP results consistent with increased risk of NTD may be followed-up with appropriate diagnostic testing as detailed in the report. MSAFP does not screen for chromosomal abnormalities.
Reference Range
Reported with patient results
Clinical Significance
Maternal serum alpha-fetoprotein (MSAFP) is used for prenatal screening. Maternal serum Alpha-Fetoprotein (AFP) elevation is associated with open neural tube defects, multiple gestation, placental anomalies, ventral abdominal wall defects, congenital nephrosis, and oligohydramnios. Follow-up for abnormal AFP results include genetic counseling, level II or III ultrasound examination and consideration of amniocentesis for chromosome and AFP analysis. MSAFP is not to be used as a screening test for chromosomal abnormalities.
Performing Laboratory
QUEST DIAGNOSTICS BALTIMORE
